Drug Safety

Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus (SLE). However, outcomes of therapies within the same class (i.e. BAFF-…

The last day was jammed with important reports and research including the late breaking abstracts.    What imaging modality is best in GCA? Dutch study: n=42 ?GCA got all three of USS,…

A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized.  Opioid use can…

One of the enduring legacies of ACR 2022 for me will be the emphasis on polymyalgia rheumatica (PMR). Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been…

Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more. Here are the RheumNow faculty…

Much has been written about tapering medications in rheumatic diseases, often due to high costs of medications, a desire to avoid side effects and patient preference to take less medications (…

Is there finally something new on the horizon in Sjogren’s syndrome?  At the second plenary session, Dr. Thomas Dorner presented abstract 1113 on a medication that may at long last be a disease…

The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of…

Recently the FDA approved deucravacitinib (DEUC), a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in systemic lupus erythematosus.…

The management of rheumatoid arthritis patients with a history of cancer continues to be an area of concern for rheumatologists. General recommendations are to treat patients with a history of solid…